These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21125043)

  • 21. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis.
    Henriksen K; Bollerslev J; Everts V; Karsdal MA
    Endocr Rev; 2011 Feb; 32(1):31-63. PubMed ID: 20851921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
    [No Abstract]   [Full Text] [Related]  

  • 25. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis.
    Soysa NS; Alles N; Weih D; Lovas A; Mian AH; Shimokawa H; Yasuda H; Weih F; Jimi E; Ohya K; Aoki K
    J Bone Miner Res; 2010 Apr; 25(4):809-18. PubMed ID: 19839765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in bone biology and new treatments for bone loss.
    Gallagher JC
    Maturitas; 2008 May; 60(1):65-9. PubMed ID: 18555623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of denosumab in prostate cancer.
    Helo S; Manger JP; Krupski TL
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):231-6. PubMed ID: 22370723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An autoimmune-mediated strategy for prophylactic breast cancer vaccination.
    Womens Health (Lond); 2010 Jul; 6(4):493. PubMed ID: 20597611
    [No Abstract]   [Full Text] [Related]  

  • 31. Drugs for postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2008 Oct; 6(74):67-74; quiz 75-6. PubMed ID: 18800025
    [No Abstract]   [Full Text] [Related]  

  • 32. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.
    Crockett JC; Mellis DJ; Scott DI; Helfrich MH
    Osteoporos Int; 2011 Jan; 22(1):1-20. PubMed ID: 20458572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A; Goessl C
    Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advances treatment of osteoporosis: new molecules, new strategies].
    Orcel P
    Bull Acad Natl Med; 2010 Nov; 194(8):1505-16; discussion 1516-8. PubMed ID: 22046713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunolocalization of the prostaglandin E2 receptor subtypes in human bone tissue: differences in foetal, adult normal, osteoporotic and pagetic bone.
    Fortier I; Gallant MA; Hackett JA; Patry C; de Brum-Fernandes AJ
    Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):431-9. PubMed ID: 15062845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
    Delmas PD
    J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Denosumab, the rheumatologist's joker?].
    Bérengère AR
    Rev Med Suisse; 2009 Jan; 5(185):59-62. PubMed ID: 19216327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the rank of RANKL in spondylarthritis?
    Loddenkemper K; Burmester GR
    Arthritis Rheum; 2008 Mar; 58(3):641-4. PubMed ID: 18311809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.